How do you pay?

How to pay the least

Cash price

$990+ for 30 tablets

Pharmacies pay about this for Rybelsus; you’d pay more.

  1. Ask your pharmacy for Rybelsus’s cash price, and one or two other pharmacies too.
  2. Rybelsus’s savings card works only with insurance from a job or one you bought.

No generic is sold yet.

Compare every option

Question
Brand nameRybelsus
Authorized genericsemaglutide
Regular genericsemaglutide
What you’d pay
At least$990for 30 tablets; pharmacies pay this
Not soldThere isn’t one
Not soldNone sold yet
Same as Rybelsus?
The original
–
–

Brand nameThe maker’s card

RYBELSUS Savings Offer

Savings card from Novo Nordisk

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $25 a prescription

The card takes up to $100 a month off your co-pay.

Sign up on novocare.com 

See the offer on rybelsus.com

In the maker’s words

“If eligible, you may PAY AS LITTLE AS $25 for a 1-, 2-, or 3-month prescription of…”

From the maker’s offer on rybelsus.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Rybelsus itself, from the same company, sold without the brand name, and usually for less. For now Rybelsus is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

No generic is sold yet. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

RYBELSUS and OZEMPIC tablets are glucagon-like peptide-1 (GLP-1) receptor agonists indicated:

  • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.

Source: the FDA label for Rybelsus (Novo Nordisk Pharmaceutical Industries, LP), January 30, 2026. Full label on DailyMed 

Good to know